Skip to main content
TipRanks
Go Ultimate75% OFF

Waters (WAT) AI Stock Analysis

468 Followers
WAT

Waters

(NYSE:WAT)

Select Model
Rating:59Neutral
Price Target:$481.00â–²(6.08% Upside)
Action:reiterated
Date:11/04/26

The score is held back primarily by weakened current (TTM) profitability and cash-flow conversion, despite solid longer-term cash generation and manageable leverage trends. Technicals are supportive with a strong trend above key moving averages and positive MACD. However, valuation is a major negative due to the extremely high P/E, partially offset by a notably upbeat earnings call with raised guidance and synergy/cost-savings progress.

Positive Factors
Recurring Installed-Base RevenueWaters combines higher-value instrument sales with repeat consumables, service contracts and software revenue. Once customers standardize workflows on its platforms, ongoing utilization can support repeat purchasing and create a more durable revenue base than equipment sales alone.
Negative Factors
Sharp TTM Margin CompressionThe latest profitability reset materially weakens current earnings quality despite strong revenue growth. If low margins persist, Waters may have less operating leverage, reduced returns on its expanded asset base and less flexibility to absorb integration costs or invest for growth.

Waters Key Performance Indicators (KPIs)

Total Recurring RevenueMeasures the revenue from ongoing customer subscriptions or services, indicating the stability and predictability of the company’s income stream.

$0.00$100.00M$200.00M$300.00M$400.00M$500.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25
Chart Insights

Total recurring revenue shows steady, seasonal rises with clear step‑ups after the acquisition of Biosciences and Diagnostic Solutions; growth is accelerating as management pursues instrument replacements, service attachments and cross‑sell synergies. Q1 dips look cyclical rather than structural, and product/regulatory wins plus a $50M revenue‑synergy plan and 180‑day commercial push signal further recurring upside—but near‑term volatility from China/export constraints and respiratory testing weakness could temper quarter‑to‑quarter consistency until synergies fully scale.

Data provided by:The Fly

Waters (WAT) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%30%WAT+20.51%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$44.56B
Dividend Yield
―
Average Volume (3M)
829.66K
Price to Earnings (P/E)
192.9
Beta (1Y)
0.93
Revenue Growth
80.68%
EPS Growth
-78.49%
Country
US
Employees
15,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Waters Business Overview & Revenue Model

Company Description

Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactu...

How the Company Makes Money

Waters primarily makes money by selling analytical instrumentation and then generating recurring revenue from the installed base through consumables and services. Key revenue streams include: (1) Instrument sales: Revenue from capital equipment such...

Waters Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:0.87%|Next Earnings Date:Feb 17, 2027
Earnings Call SentimentPositive

The call was strongly positive. Highlights significantly outweighed the challenges, with double-digit organic growth, a 21% adjusted EPS increase, raised full-year revenue and EPS guidance, improving acquired-business execution, strong product and AI momentum, cost-savings progress and a constructive 2027 framework. The main negatives were limited reported growth in the acquired businesses, China DRG and channel-inventory headwinds, constrained free cash flow, elevated inventory and acquisition-related costs.

Positive Updates

Strong Third-Quarter Revenue and EPS Growth
Total company as-reported revenue was $1.767 billion, including $871 million of organic revenue and $896 million from Waters Bioscience and Waters Diagnostic Solutions. Organic revenue grew 9% as reported and 10% in constant currency, while adjusted EPS increased 21% to $4.10, $0.05 above the high end of guidance.

Negative Updates

Acquired Businesses Delivered Limited Reported Growth
Biosciences and Diagnostic Solutions generated $896 million of third-quarter revenue, representing only 1% reported growth year over year. Diagnostic Solutions was flat on a reported basis, as expected.

Company Guidance

For 2026, organic constant currency revenue growth guidance was raised 140 basis points at the midpoint to 9.1% to 9.7%, with organic reported revenue expected at $3.429 billion to $3.447 billion; Biosciences and Diagnostic Solutions revenue is expected to be approximately $3.05 billion, a $5 million raise, and total reported revenue is expected to be approximately $6.479 billion to $6.497 billion, a $43 million raise at the midpoint. Full year adjusted EBIT margin is expected to be 28.2%, net interest expense $196 million, the tax rate 15.4%, and adjusted earnings per fully diluted share $14.60 to $14.70, representing year-over-year growth of 11% to 12% and 13% to 14% in constant currency. Fourth quarter organic constant currency revenue growth is expected to be 7% to 9%, organic reported revenue $984 million to $1.002 billion, Biosciences and Diagnostic Solutions revenue approximately $817 million, total reported revenue $1.801 billion to $1.819 billion, and adjusted earnings per fully diluted share $4.58 to $4.68; on a days adjusted basis, guidance reflects 9% to 11% organic growth and approximately 10% reported growth for acquired businesses. For 2027, the starting assumption is legacy Waters growing high single digits and legacy BD growing mid-single digits, combining to mid-single-digit plus organic growth, with a critical path to a high single-digit growth potential for the combined company, 100 basis points of adjusted operating margin expansion to 29.2%, low teens adjusted EPS growth, and mid-teens as the upside case; revenue synergies are underwritten at another $60 million added in 2027 over and above the $50 million in 2026.

Waters Financial Statement Overview

Summary

Multi-year results show a profitable, cash-generative profile with improving leverage trends, but the latest TTM shows a sharp profitability reset (net and operating margins falling to low-single digits) and meaningfully lower free cash flow versus the prior year. Balance-sheet leverage appears manageable, yet the near-term earnings quality and return deterioration weighs heavily.

Income Statement

42Neutral

Balance Sheet

55Neutral

Cash Flow

58Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue5.61B3.17B2.96B2.96B2.97B2.79B
Gross Profit2.77B1.88B1.76B1.76B1.72B1.63B
EBITDA1.13B1.01B1.04B1.00B1.02B982.81M
Net Income98.21M642.63M637.83M642.23M707.75M692.84M
Balance Sheet
Total Assets24.11B5.08B4.55B4.63B3.28B3.09B
Cash, Cash Equivalents and Short-Term Investments593.00M587.83M325.36M395.97M481.39M569.28M
Total Debt5.50B1.49B1.70B2.44B1.66B1.60B
Total Liabilities8.82B2.52B2.73B3.48B2.78B2.73B
Stockholders Equity15.29B2.56B1.83B1.15B504.49M367.55M
Cash Flow
Free Cash Flow291.58M539.81M619.64M442.18M428.20M579.01M
Operating Cash Flow460.55M652.55M762.12M602.81M611.66M747.27M
Investing Cash Flow-39.13M-152.25M-144.02M-1.44B-107.97M-231.63M
Financing Cash Flow-276.66M-237.21M-696.67M754.95M-509.63M-438.27M

Waters Technical Analysis

Technical Analysis SentimentNeutral
Last Price453.42

Price Trends

50DMA441.09Positive
100DMA416.40Positive
200DMA373.61Positive

Market Momentum

MACD6.21Positive
RSI49.10Neutral
STOCH27.92Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WAT, the sentiment is Neutral. The current price of 453.42 is below the 20-day moving average (MA) of 462.02, above the 50-day MA of 441.09, and above the 200-day MA of 373.61, indicating a neutral trend. The MACD of 6.21 indicates Positive momentum. The RSI at 49.10 is Neutral, neither overbought nor oversold. The STOCH value of 27.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for WAT.

Waters Risk Analysis

Waters disclosed 2 risk factors in its most recent earnings report. Waters reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk
1.Item 1: Legal ProceedingsQ3, 2025

Waters Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

WAT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TMOTMO77Outperform$256.15B36.4013.31%0.27%8.27%9.59%
AA75Outperform$48.75B34.0120.47%0.59%8.60%19.07%
MTDMTD75Outperform$34.36B37.389999.00%―6.51%15.03%
RVTYRVTY74Outperform$16.62B66.183.50%0.19%4.56%13.22%
DHRDHR73Outperform$161.75B37.788.18%0.66%5.52%25.53%
WATWAT59Neutral$44.56B192.940.81%―80.68%-78.49%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%75%WATADHRMTDRVTYTMODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
WAT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
WATWaters Corp453.4276.7920.39%
AAgilent Technologies172.9230.1521.12%
DHRDanaher Corporation229.916.052.70%
MTDMettler-toledo International1727.26330.8123.69%
RVTYRevvity, Inc.148.8556.0260.35%
TMOThermo Fisher Scientific691.33117.3220.44%

Waters Corporate Events

Business Operations and StrategyExecutive/Board Changes

Waters Announces Leadership Change in Analytical Sciences Division

Neutral
Aug 21, 2026

On August 17, 2026, Waters Corporation announced that Robert L. Carpio III had decided to resign from his role as Senior Vice President of the Waters Analytical Sciences Division to pursue other opportunities, relinquishing his duties effective Augus...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026